Dr Schlechter on TAC01-HER2 Therapy in HER2+ Solid Tumors

Benjamin L. Schlechter, MD, discusses the future implications of TAC01-HER2 therapy in patients with HER2-positive solid tumors.

Related Keywords

Benjaminl Schlechter , ,Dana Farber Cancer Institute ,Harvard Medical School ,D ,Tac01 Her2 Therapy ,Patients With Her2 Positive Solid Tumors ,Tactic 2 Trial ,Nct04727151 ,